All In Biotech

Drug Trial Radar · NCT01725087

Efficacy and Safety of GRT6005 in Patients With Chronic Low Back Pain.

Efficacy, Safety, and Tolerability of GRT6005 in Subjects With Moderate to Severe Chronic Low Back Pain.

Last checked: Nov 20, 2026Latest source record: Jul 15, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 1,089 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,089

Actual

Start

Nov 2012

Primary completion

Jul 2014

Study completion Jul 2014

Sponsor

Lead sponsor
Tris Pharma, Inc.Industry
Sponsor type
Industry
Collaborators
Forest Laboratories
First posted
Nov 12, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this trial is to evaluate the safety and efficacy of once daily orally administered GRT6005 in a total of 3 fixed doses compared to placebo in subjects with moderate to severe chronic Low Back Pain (LBP). The study includes a maximum of 21 days screening period followed by a 2-week titration period and 12-week maintenance double-blind treatment period and a 10-14 day safety follow up period. Patients who are eligible for the double-blind treatment period will be randomized to one of the following treatment groups: GRT6005 low-dose, GRT6005 medium dose, GRT6005 high-dose, Tapentadol or placebo.

Conditions

  • Low Back Pain

Interventions

  • Matching PlaceboDrug

  • Low Dose GRT6005Drug

  • Medium Dose GRT6005Drug

  • High Dose GRT6005Drug

  • TapentadolDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. European Union: the change from baseline pain to the weekly average 24-hour pain during the entire 12 weeks of the maintenance phase of the double-blind Treatment Period.Time frame: Baseline to End of Treatment (Week 14)
  2. United States: the change from baseline pain to the average 24-hour pain during Week 12 of the maintenance phase.Time frame: Baseline to End of Treatment (Week 14)

Locations

79 sites in 11 countries. Site status is shown where the registry gives one.

  • AT003

    Senftenberg, Austria

  • AT004

    Vienna, Austria

  • AT001

    Vienna, Austria

  • AT005

    Vienna, Austria

  • AT006

    Vienna, Austria

  • BE001

    Brussels, Belgium

  • BE002

    Edegem, Belgium

  • BE004

    Genk, Belgium

  • DK004

    Aalborg, Denmark

  • DK001

    Frederiksberg, Denmark

  • Site DK002

    Glostrup Municipality, Denmark

  • DK003

    Odense, Denmark

  • FI005

    Kokkola, Finland

  • FI001

    Kuopio, Finland

  • FI003

    Lahti, Finland

  • DE005

    Bad Nauheim, Germany

  • DE014

    Berlin, Germany

  • DE018

    Berlin, Germany

  • DE011

    Bochum, Germany

  • DE015

    Böhlen, Germany

  • DE007

    Dresden, Germany

  • DE016

    Essen, Germany

  • DE001

    Hamburg, Germany

  • DE006

    Hamburg, Germany

  • DE008

    Hanover, Germany

  • DE002

    Leipzig, Germany

  • DE019

    Leipzig, Germany

  • DE009

    Mosbach, Germany

  • DE004

    Munich, Germany

  • DE013

    Rodgau, Germany

  • DE017

    Wiesbaden, Germany

  • HU010

    Baja, Hungary

  • HU008

    Békéscsaba, Hungary

  • HU011

    Budapest, Hungary

  • HU015

    Budapest, Hungary

  • HU005

    Budapest, Hungary

  • HU012

    Budapest, Hungary

  • HU003

    Kecskemét, Hungary

  • HU002

    Kiskunfélegyháza, Hungary

  • HU001

    Makó, Hungary

Showing 40 of 79 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.